Deucravacitinib — Membership Pricing

Other medications in Rheumatology

• Etanercept
• Filgotinib
• Guselkumab
• Ixekizumab
• Mycophenolate
• Probenecid
• Rilonacept
• Risankizumab

About Deucravacitinib

Deucravacitinib offers a targeted approach for adults living with moderate-to-severe plaque psoriasis, aiming to significantly improve skin clarity. As a leading prescription savings membership, TheDrugClub is dedicated to helping our members access innovative treatments like deucravacitinib more affordably, making a real difference in managing chronic conditions.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Deucravacitinib is approved for (FDA label)

SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor indicated for: • the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other potent immunosuppressants. • the treatment of active psoriatic arthritis in adults. ( 1.2 ) 1.1 Plaque Psoriasis SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use : SOTYKTU is not recommended for use in combination with other potent immunosuppressants. 1.2 Psoriatic Arthritis SOTYKTU is indicated for the treatment of active psoriatic arthritis in adults.

Source: Read the full FDA label on DailyMed. Label effective date: June 30, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Deucravacitinib (FDA label)

Tablets: 6 mg of deucravacitinib, pink, round, biconvex, marked with “BMS 895” and “6 mg” on one side with no content on the other side. Tablets: 6 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: ff4d7258-5068-4cdf-9692-8cae04c3198e. SPL document ID: 73204bef-9921-40ed-9230-ba35953c99c4. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Deucravacitinib (FDA label)

The following adverse reactions are discussed in greater detail in other sections of labeling: • Infections [see Warnings and Precautions (5.2) ] • Malignancy including Lymphomas [see Warnings and Precautions (5.4) ] • Elevated CPK [see Warnings and Precautions (5.5) ] • Laboratory Abnormalities [see Warnings and Precautions (5.6) ] Most common adverse reactions (≥ 1%) are: upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, and acne. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: ff4d7258-5068-4cdf-9692-8cae04c3198e. SPL document ID: 73204bef-9921-40ed-9230-ba35953c99c4. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Deucravacitinib (FDA label)

SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU [see Warnings and Precautions (5.1) ] . History of hypersensitivity reaction to deucravacitinib or any of the excipients in SOTYKTU. ( 4 , 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: ff4d7258-5068-4cdf-9692-8cae04c3198e. SPL document ID: 73204bef-9921-40ed-9230-ba35953c99c4. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Deucravacitinib (FDA label)

• Hypersensitivity Reactions: Hypersensitivity reactions, such as angioedema, have been reported. Discontinue if a clinically significant hypersensitivity reaction occurs. (5.1) • Infections: SOTYKTU may increase the risk of infection. Avoid use in patients with active or serious infection. If a serious infection develops, discontinue SOTYKTU until the infection resolves. (5.2) • Tuberculosis: Evaluate for latent or active TB prior to initiating treatment with SOTYKTU. (5.3) • Malignancy: Malignancies including lymphomas were observed in clinical trials with SOTYKTU. Consider the benefits and risks prior to initiating or continuing SOTYKTU in patients with a malignancy. (5.4) • Rhabdomyolysis and Elevated CPK: Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected . (5.5) • Laboratory Abnormalities: Periodically evaluate serum triglycerides.

Source: FDA prescribing information (DailyMed). Set ID: ff4d7258-5068-4cdf-9692-8cae04c3198e. SPL document ID: 73204bef-9921-40ed-9230-ba35953c99c4. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.